p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.

Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, Han QX, Shen ZZ, Fontana JA
Int J Cancer. 1997 74 (5): 529-34

PMID: 9355976 · DOI:10.1002/(sici)1097-0215(19971021)74:5<529::aid-ijc9>3.0.co;2-5

p21/waf1/cip1 and mdm-2 are downstream effectors of p53. p21 plays a major role in negatively regulating cell-cycle progression, while mdm-2 inhibits p53 effects, and its role has been implicated in oncogenesis. In this study, we investigated the expression profiles of p21, mdm-2 and p53 in human breast-carcinoma tissues. The aim was to determine whether a correlation exists between the expression profiles of these markers and tumor differentiation, ER status and prognosis. We studied tumor specimens obtained from 106 patients and found a highly significant association among low histology grade, p53 over-expression, high mdm-2 expression and lack of p21 expression. Our studies also demonstrate that, in human breast cancer, low levels of p21 and higher mdm-2 levels directly correlate with the onset of lymph-node metastases and shortened patient survival. Furthermore, the expression profiles of p21, mdm-2 and p53 were independently correlated with patient survival.

MeSH Terms (20)

Adult Aged Breast Neoplasms Cell Differentiation Cyclin-Dependent Kinase Inhibitor p21 Cyclins Female Humans Immunohistochemistry Lymphatic Metastasis Middle Aged Multivariate Analysis Neoplasm Proteins Nuclear Proteins Phenotype Prognosis Proto-Oncogene Proteins Proto-Oncogene Proteins c-mdm2 Receptors, Estrogen Tumor Suppressor Protein p53

Connections (1)

This publication is referenced by other Labnodes entities: